Market claims and efficacy information in direct‐to‐consumer prescription drug print advertisements-Reference-Cited by-同舟云学术

Market claims and efficacy information in direct‐to‐consumer prescription drug print advertisements

Published:2019-03-29 Issue:8 Volume:36 Page:747-757
ISSN:0742-6046
Container-title:Psychology & Marketing
language:en
Short-container-title:Psychol Mark

Author:

Aikin Kathryn J.¹^ORCID,Betts Kevin R.¹,Keisler Aysha²,Ziemer Kathryn Schaefer²

Affiliation:

1. Office of Prescription Drug Promotion, U.S. Food and Drug AdministrationSilver Spring Maryland

2. Ipsos Public AffairsWashington District of Columbia

Publisher

Wiley

Subject

Marketing,Applied Psychology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mar.21209

Reference21 articles.

1. Effects of Prior Knowledge and Experience and Phase of the Choice Process on Consumer Decision Processes: A Protocol Analysis

2. Validation of Screening Questions for Limited Health Literacy in a Large VA Outpatient Population

3. Marketing Drugs, Marketing Health Care Relationships: A Content Analysis of Visual Cues in Direct-to-Consumer Prescription Drug Advertising

4. Effects of Price, Brand, and Store Information on Buyers' Product Evaluations

5. Food and Drug Administration. (2009). Guidance for industry: Presenting risk information in prescription drug and medical device promotion: Draft guidance. Washington DC. Retrieved fromhttps://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM155480.pdf.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A scoping review of empirical research on prescription drug promotion;Research in Social and Administrative Pharmacy;2023-06

2. Implied Claims in Drug Advertising: A Review of Recent Literature and Regulatory Actions;Health Communication;2023-02-24

3. Nutrition labeling, numerosity effects, and vigilance among diet‐sensitive individuals;Psychology & Marketing;2022-11-25

4. A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility;Value in Health;2021-12

5. The FDA’s Diverse and Dynamic Activities in the Social and Behavioral Sciences: Advancing and Supporting Health Equity;Journal of Primary Care & Community Health;2021-01